Amisulpride vs. risperidone in the treatment of acute exacerbations of schizophrenia (Q60445497)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10622347%20AND%20SRC:MED&resulttype=core&format=json

3 November 2019

title

Amisulpride vs. risperidone in the treatment of acute exacerbations of schizophrenia. Amisulpride study group (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10622347%20AND%20SRC:MED&resulttype=core&format=json

3 November 2019

1 reference

1 reference

J Peuskens

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10622347%20AND%20SRC:MED&resulttype=core&format=json

3 November 2019

R Bale

series ordinal

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10622347%20AND%20SRC:MED&resulttype=core&format=json

3 November 2019

O Fleurot

series ordinal

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10622347%20AND%20SRC:MED&resulttype=core&format=json

3 November 2019

W Rein

series ordinal

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10622347%20AND%20SRC:MED&resulttype=core&format=json

3 November 2019

language of work or name

English

0 references

publication date

1 November 1999

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10622347%20AND%20SRC:MED&resulttype=core&format=json

3 November 2019

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10622347%20AND%20SRC:MED&resulttype=core&format=json

3 November 2019

volume

88

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10622347%20AND%20SRC:MED&resulttype=core&format=json

3 November 2019

issue

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10622347%20AND%20SRC:MED&resulttype=core&format=json

3 November 2019

page(s)

107-117

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10622347%20AND%20SRC:MED&resulttype=core&format=json

Multiple fixed doses of "Seroquel" (quetiapine) in patients with acute exacerbation of schizophrenia: a comparison with haloperidol and placebo. The Seroquel Trial 13 Study Group

3 November 2019

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0165-1781%2899%2900075-X

7 January 2021

Tardive dyskinesia: summary of a Task Force Report of the American Psychiatric Association. By the Task Force on Late Neurological Effects of Antipsychotic Drugs

1 reference

https://api.crossref.org/works/10.1016%2FS0165-1781%2899%2900075-X

7 January 2021

A rating scale for drug-induced akathisia

1 reference

https://api.crossref.org/works/10.1016%2FS0165-1781%2899%2900075-X

7 January 2021

Olanzapine versus placebo: results of a double-blind, fixed-dose olanzapine trial

1 reference

https://api.crossref.org/works/10.1016%2FS0165-1781%2899%2900075-X

7 January 2021

Olanzapine versus placebo and haloperidol: acute phase results of the North American double-blind olanzapine trial

1 reference

https://api.crossref.org/works/10.1016%2FS0165-1781%2899%2900075-X

7 January 2021

Risperidone versus clozapine in treatment-resistant chronic schizophrenia: a randomized double-blind study. The Risperidone Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0165-1781%2899%2900075-X

7 January 2021

Treatment of negative symptoms in schizophrenia with amisulpride

1 reference

https://api.crossref.org/works/10.1016%2FS0165-1781%2899%2900075-X

7 January 2021

Risperidone in the treatment of negative symptoms of schizophrenia: a meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0165-1781%2899%2900075-X

7 January 2021

Positron emission tomographic analysis of central D1 and D2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine. Relation to extrapyramidal side effects

1 reference

https://api.crossref.org/works/10.1016%2FS0165-1781%2899%2900075-X

7 January 2021

Risperidone versus perphenazine in the treatment of chronic schizophrenic patients with acute exacerbations

1 reference

https://api.crossref.org/works/10.1016%2FS0165-1781%2899%2900075-X

7 January 2021

Risperidone versus zuclopenthixol in the treatment of acute schizophrenic episodes: a double-blind parallel-group trial

1 reference

https://api.crossref.org/works/10.1016%2FS0165-1781%2899%2900075-X

7 January 2021

The positive and negative syndrome scale (PANSS) for schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0165-1781%2899%2900075-X

7 January 2021

Amisulpride versus placebo in the medium-term treatment of the negative symptoms of schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0165-1781%2899%2900075-X

7 January 2021

Risperidone in the treatment of schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0165-1781%2899%2900075-X

7 January 2021

Neuroleptic treatment of negative symptoms in schizophrenic patients. Efficacy problems and methodological difficulties

1 reference

https://api.crossref.org/works/10.1016%2FS0165-1781%2899%2900075-X

7 January 2021

Improvement of acute exacerbations of schizophrenia with amisulpride: a comparison with haloperidol. PROD-ASLP Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0165-1781%2899%2900075-X

7 January 2021

Abnormal involuntary movements in patients on long-acting neuroleptics

1 reference

https://api.crossref.org/works/10.1016%2FS0165-1781%2899%2900075-X

7 January 2021

Improvement of some schizophrenic deficit symptoms with low doses of amisulpride

1 reference

https://api.crossref.org/works/10.1016%2FS0165-1781%2899%2900075-X

7 January 2021

Risperidone in the treatment of patients with chronic schizophrenia: a multi-national, multi-centre, double-blind, parallel-group study versus haloperidol. Risperidone Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0165-1781%2899%2900075-X

7 January 2021

Amisulpride, and atypical antipsychotic, in the treatment of acute episodes of schizophrenia: a dose-ranging study vs. haloperidol. The Amisulpride Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0165-1781%2899%2900075-X

7 January 2021

One-month prevalence of mental disorders in the United States. Based on five Epidemiologic Catchment Area sites

1 reference

https://api.crossref.org/works/10.1016%2FS0165-1781%2899%2900075-X

7 January 2021

The costs of schizophrenia. Assessing the burden.

1 reference

https://api.crossref.org/works/10.1016%2FS0165-1781%2899%2900075-X

7 January 2021

Deficit symptoms in schizophrenia: negative symptoms versus neuroleptic-induced deficits.

1 reference

https://api.crossref.org/works/10.1016%2FS0165-1781%2899%2900075-X

7 January 2021

The natural history of schizophrenia: a five-year follow-up study of outcome and prediction in a representative sample of schizophrenics

1 reference

https://api.crossref.org/works/10.1016%2FS0165-1781%2899%2900075-X

7 January 2021

Quetiapine in patients with schizophrenia. A high- and low-dose double-blind comparison with placebo. Seroquel Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0165-1781%2899%2900075-X

7 January 2021

Molecular cloning and characterization of a novel dopamine receptor (D3) as a target for neuroleptics

1 reference

https://api.crossref.org/works/10.1016%2FS0165-1781%2899%2900075-X

7 January 2021

Double-blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders.

1 reference

https://api.crossref.org/works/10.1016%2FS0165-1781%2899%2900075-X

7 January 2021

A randomized, controlled, dose-ranging trial of sertindole in patients with schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0165-1781%2899%2900075-X

7 January 2021

Subjective response as a predictor of outcome in pharmacotherapy: the consumer has a point

1 reference

https://api.crossref.org/works/10.1016%2FS0165-1781%2899%2900075-X

7 January 2021

Amisulpride versus flupentixol in schizophrenia with predominantly positive symptomatology -- a double-blind controlled study comparing a selective D2-like antagonist to a mixed D1-/D2-like antagonist. The Amisulpride Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0165-1781%2899%2900075-X

7 January 2021

Controlled, dose-response study of sertindole and haloperidol in the treatment of schizophrenia. Sertindole Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0165-1781%2899%2900075-X

7 January 2021

10.1016/S0165-1781(99)00075-X

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10622347%20AND%20SRC:MED&resulttype=core&format=json

3 November 2019

1 reference